Latest Commercialization News

Adisyn Ltd has completed a strategic review, deciding to boost investment in its graphene-based semiconductor arm while exploring options to unlock value from its managed IT services business.

Cavalier Resources has signed a landmark Native Title Agreement with the Wangkatja Aboriginal Corporation, clearing a major hurdle for the Crawford Gold Project. Alongside this, an updated Pre-Feasibility Study confirms robust economics underpinning near-term production.

Saluda Medical has received CE certification for its EVA™ Sensing Technology, enabling commercialisation in Europe and recognition in Australia following prior FDA approval. This milestone sets the stage for a broader rollout of its personalised spinal cord stimulation therapy in early 2026.

Blue Star Helium has successfully started helium production at its Galactica project in Colorado, positioning itself as America’s newest helium producer with sales targeted for early 2026. The company’s strategic joint venture and low-cost operations underpin a promising growth trajectory amid rising helium and CO₂ demand.

CONNEQT Health has raised $3.1 million through an institutional placement to fuel growth of its Pulse vascular health device, supported by both new and existing investors including its largest shareholder.

Blue Star Helium has successfully started helium production at its Pinon Canyon plant, marking a key milestone as it prepares for commercial sales and expansion in 2026.

Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.

Beetaloo Energy’s Carpentaria-5H well has delivered one of the highest gas flow rates in the Beetaloo Basin, showcasing promising long-term productivity and paving the way for pilot gas sales in 2026.

Clarity Pharmaceuticals has secured positive FDA guidance to initiate a pivotal Phase III trial of its Cu-64 SARTATE diagnostic agent for neuroendocrine tumours, aiming to improve detection and patient outcomes.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.

Invictus Energy has completed the Petroleum Production Sharing Agreement process for its Cabora Bassa Project, setting the stage for significant gas exploration and development in Zimbabwe.

FlexiRoam has secured a strategic partnership with Generali Insurance Malaysia to deploy its AI-driven eSIM connectivity platform through WhatsApp, targeting the growing travel insurance market.